• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $21 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-32 Mln

Yumanity Therapeutics Inc. (YMTX) Share Price

$1.89

As on 16-Dec-2022 16:00 EST

up-down-arrow $0.158.62%

  • Prev Close info

    $1.74

  • Day's Openinfo

    $--

  • Today's Highinfo

    $--

  • Today's Lowinfo

    $--

  • Today's Volumeinfo

    --

  • 52 Week rangeinfo

    $-- - --

Please wait...

Yumanity Therapeutics Inc. (YMTX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Yumanity Therapeutics (YMTX)
-36.15 3.85 8.00 -38.83 -23.67 -17.65 --
S&P BSE Sensex*
0.09 2.27 9.60 21.95 13.77 15.03 13.17
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 16-Dec-2022  |  *As on 28-Feb-2024  |  #As on 26-Oct-2023
2021
2020
2019
2018
2017
Yumanity Therapeutics (YMTX)
-82.59 -62.72 -29.63 -44.25 -52.45
S&P Small-Cap 600
25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Yumanity Therapeutics Inc. (YMTX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Yumanity Therapeutics Inc. (YMTX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Yumanity Therapeutics Inc. (YMTX)

        CEO, Pres & Director

        Dr. Richard Peters M.D., Ph.D.

        Scientific Co-Founder & Sr. Advisor of Discovery Biology

        Dr. Vikram Khurana M.D., Ph.D.

        Headquarters

        Boston, MA

        FAQs for Yumanity Therapeutics Inc. (YMTX)

        The total asset value of Yumanity Therapeutics Inc. (YMTX) stood at $ 14 Mln as on 30-Sep-22

        The share price of Yumanity Therapeutics Inc. (YMTX) is $1.89 (NASDAQ) as of 16-Dec-2022 16:00 EST. Yumanity Therapeutics Inc. (YMTX) has given a return of -23.67% in the last 3 years.

        Yumanity Therapeutics Inc. (YMTX) has a market capitalisation of $ 21 Mln as on 13-Jan-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Yumanity Therapeutics Inc. (YMTX) is 3.33 times as on 13-Jan-2023, a 0.12% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Yumanity Therapeutics Inc. (YMTX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Yumanity Therapeutics Inc. (YMTX) and enter the required number of quantities and click on buy to purchase the shares of Yumanity Therapeutics Inc. (YMTX).

        Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

        The CEO & director of Dr. Richard Peters M.D., Ph.D.. is Yumanity Therapeutics Inc. (YMTX), and CFO & Sr. VP is Dr. Vikram Khurana M.D., Ph.D..

        The promoters of Yumanity Therapeutics Inc. (YMTX) have pledged 0% of the total equity as on Sep-22.

        Some of the close peers are:

        Company Market Cap($ Mln)
        Yumanity Therapeutics Inc. (YMTX) Ratios
        Return on equity(%)
        -372.55
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Yumanity Therapeutics Inc. (YMTX) was $-32 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $20.52 Mln
        • Revenue (TTM)revenue-information $4.84 Mln
        • Earnings (TTM) earning-information $-32.00 Mln
        • Cash date-information $8.42 Mln
        • Total Debt info $0.20 Mln
        • Insider's Holding 19.62%
        • Liquidity liquidity
        • 52 Week range week-range $-- - --
        • Shares outstanding share-outstanding 10,856,500

        About The Company

        • IPO Date 11-Feb-2016
        • CEO, Pres & Director Dr. Richard Peters M.D., Ph.D.
        • Scientific Co-Founder & Sr. Advisor of Discovery Biology Dr. Vikram Khurana M.D., Ph.D.
        • Listing key-listing NASDAQ: YMTX
        • Country United States
        • Headquarters headquarters Boston, MA
        • Website website https://www.yumanity.com
        • Business

          Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies...  to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.  Read more

        share-fund-plan-icon